Last edition
News about "investigational oral therapy "
US FDA Grants Breakthrough Therapy Designation to Lilly's Olomorasib for Advanced Pancreatic Cancer
The US FDA has granted Breakthrough Therapy designation to Eli Lilly's investigational KRAS G12C inhibitor, olomorasib, for treating previously treated advanced pancreatic cancer, reinforcing its potential across difficult-to-treat KRAS-driven cancers.
Investigational Oral Therapy | 04/08/2026 | By News Bureau
MerryLife Biomedical Reports Positive Phase I Data for Oral Alzheimer's Therapy TML-6
MerryLife Biomedical’s investigational oral therapy TML-6 demonstrated favourable safety and tolerability in Phase I, paving the way for a 210-patient global Phase II trial in early Alzheimer’s disease.
Investigational Oral Therapy | 10/02/2026 | By News Bureau | 154
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy